acarbose/obesity

Lyen an sove nan clipboard la

Chwazi kalite sòt

Paj 1 soti nan 220 rezilta yo

The effect of acarbose on insulin sensitivity and proinsulin in overweight subjects with impaired glucose tolerance.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Insulin sensitivity is impaired in overweight subjects with IGT and is accompanied by hyperinsulinemia, a condition, that might promote early B-cell exhaustion. Twelve subjects were recruited for a double-blind trial using either 100 mg of acarbose or placebo for three months. Insulin sensitivity

Evaluation of effect of acarbose consumption on weight losing in non-diabetic overweight or obese patients in Kerman.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND High prevalence of obesity and the importance of this issue as a risk factor for chronic diseases such as severe cardiovascular diseases, diabetes, and cancer necessitate the need for treatment. The aim of this study was the evaluation of acarbose effect on the weight loss in non diabetic

Acarbose in obese patients with polycystic ovarian syndrome: a double-blind, randomized, placebo-controlled study.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND The present study assessed the effects of low-dose acarbose on obese patients with polycystic ovarian syndrome (PCOS). METHODS A double-blind placebo-controlled study was conducted on 30 obese hyperinsulinaemic women with PCOS treated with 150 mg/day acarbose or placebo for 6 months. The

The effect of acarbose on insulin resistance in obese hypertensive subjects with normal glucose tolerance: a randomized controlled study.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

OBJECTIVE Acarbose, a glucose oxidase inhibitor, delays the absorption of glucose thus reducing post-prandial blood glucose level, haemoglobin A1c (HbA1c) and insulin resistance in patients with diabetes mellitus and in subjects with impaired glucose tolerance. The effect of acarbose in subjects

Effects of chronic acarbose treatment on adipocyte insulin responsiveness, serum levels of leptin and adiponectin and hypothalamic NPY expression in obese diabetic Wistar rats.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

1. Inhibitors of intestinal glucosidases have been shown to improve glycaemic control in diabetic and obese humans and animals. In the present study, we have investigated the effect of 3 months treatment with acarbose on adiposity, food intake and the modulation of hypothalamic neuropeptide Y (NPY)

Effects of chronic treatment with acarbose on glucose and lipid metabolism in obese diabetic Wistar rats.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

OBJECTIVE The effect of chronic treatment with acarbose on fasting plasma glucose, insulin, triglyceride, cholesterol and free fatty acid (FFA) concentrations, as well as on the glucose and insulin excursions during oral glucose tolerance test (OGTT), in obese diabetic Wistar (WDF) rats was

Acarbose treatment in obesity: a controlled study.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Acarbose is an alpha-glucosidase inhibitor which reversibly inhibits oligosaccharidase and disaccharidase at the brush border of the small intestine. The aim of this study was to observe its effectiveness in the treatment of obesity. METHODS Two groups of 25 obese women were put on a 15 kcal/kg/day

Effect of acarbose on weight maintenance after dietary weight loss in obese subjects.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

OBJECTIVE Acarbose is a well established antidiabetic drug and is known to exert a modest weight-lowering effect. The aim of this study was to assess the potential of acarbose to improve weight maintenance after a substantial weight loss by dietary measures in obese subjects. METHODS Randomised,

Effectiveness of acarbose, an alpha-glucosidase inhibitor, in uncontrolled non-obese non-insulin dependent diabetes.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

The effect of acarbose, an alpha-glucosidase inhibitor, on glycaemic control, was compared with placebo in a double-blind, randomised, group comparison study during 16 weeks in 20 non-obese non-insulin dependent diabetic patients in whom sulphonylurea treatment had been withdrawn. There was

The alpha-glucosidase inhibitor acarbose prevents obesity and simple steatosis in sequestosome 1/A170/p62 deficient mice.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

OBJECTIVE Sequestosome 1 (SQSTM1)/A170/p62 plays an important role in membrane-receptor mediated signal transduction and autophagic protein degradation. Although the mechanism involved is not clear, sqstm1 gene knockout (KO) mice develop mature-onset obesity and insulin resistance, leading to type

Sleep patterns in the genetically obese Zucker rat: effect of acarbose treatment.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Sleep patterns were continuously recorded in the genetically obese Zucker rat. Under normal feeding conditions, Zucker rats showed large amounts of slow-wave sleep (SWS) and normal amounts of pardoxical sleep (PS). In addition, both SWS and PS were equally distributed throughout the nychthemeron.

[Short term assessment of anthropometric indices and metabolic parameters in obese subjects treated with acarbose].

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Acarbose represents the first of a new class of oral antidiabetic drugs: the alpha-glucosidases inhibitors. This drug in fact delays the production of monosacchtarides inhibiting the alpha-glucosidases of the small bowel, that are responsible of digestion of complex polysaccharides and sucrose. In

Long-term efficacy and safety of acarbose in the treatment of obese subjects with non-insulin-dependent diabetes mellitus.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND Acarbose delays the release of glucose from complex carbohydrates and disaccharides by inhibiting intestinal alpha-glucosidases, attenuating postprandial increments in blood glucose and insulin. This multicenter double-blind study compared the efficacy and safety of acarbose with placebo

Acarbose versus trans-chalcone: comparing the effect of two glycosidase inhibitors on obese mice.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

OBJECTIVE Acarbose and trans-chalcone are glucosidase inhibitors whose beneficial effects have been demonstrated in diabetes. The present study aimed at investigating their potential effects in obesity. METHODS NMRI male mice (n = 48) were subjected to a high fat diet for four weeks, which induced

Retrospective comparison of voglibose or acarbose as an add-on therapy to sulfonylureas in Western Indian patients with uncontrolled overweight/obese type 2 diabetes.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

OBJECTIVE The study was aimed to investigate the effect of voglibose or acarbose as an add-on treatment in overweight/obese type 2 diabetes (T2DM) patients who are uncontrolled with metformin and sulfonylureas (SUs) in Western part of India. METHODS A retrospective study included 77 participants

Antre nan paj
facebook nou an

Herbal & Natural Medicine

Baz done ki pi konplè remèd fèy medsin te apiye nan syans

Travay nan 55 lang
Geri èrbal te apiye nan syans
Remèd fèy rekonesans pa imaj
Kat entèaktif GPS - tag zèb sou kote (vini byento)
Li piblikasyon syantifik ki gen rapò ak rechèch ou an
Search remèd fèy medsin pa efè yo
Izeganize enterè ou yo ak rete kanpe fè dat ak rechèch la nouvèl, esè klinik ak rive

Tape yon sentòm oswa yon maladi epi li sou remèd fèy ki ta ka ede, tape yon zèb ak wè maladi ak sentòm li itilize kont.
* Tout enfòmasyon baze sou rechèch syantifik pibliye